

REVA MEDICAL, INC.
Reported by
SENRIGAN CAPITAL GROUP LTD

FORM 5
(Annual Statement of Changes in Beneficial Ownership)

Filed 02/14/17 for the Period Ending 02/14/17

Address 5751 COPLEY DRIVE
SAN DIEGO, CA 92111
Telephone (858) 966-3000
CIK 0001496268
Symbol RVALL
SIC Code 3842 - Orthopedic, Prosthetic, and Surgical Appliances and Supplies
Industry Advanced Medical Equipment & Technology
Sector Healthcare
Fiscal Year 12/31

FORM 5

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL
OMB Number: 3235-0362
Estimated average burden
hours per response... 1.0

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
 Form 3 Holdings Reported
 Form 4 Transactions Reported

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or
Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Senrigan Capital Group Ltd (Last) (First) (Middle) 1504 15TH FLOOR WHEELOCK HOUSE, 20 PEDDER STREET, CENTRAL (Street) HONG KONG, K3 00000 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol REVA Medical, Inc. [RVA:AX] 3. Statement for Issuer's Fiscal Year Ended (MM/DD/YYYY) <p align="center">2/14/2017</p>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)
4. If Amendment, Date Original Filed (MM/DD/YYYY)		6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form Filed by One Reporting Person <input checked="" type="checkbox"/> Form Filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Amount	(A) or (D)	Price				
Common Stock, par value \$0.0001 per share	7/7/2016		J4	0	(1)(2)(3) (4)(5)(6)(7) (8)(9)	A	(8)(9)	6219271	I	See footnotes
Common Stock, par value \$0.0001 per share	7/13/2016		J4	0	(1)(2)(3) (4)(5)(6)(7) (8)(9)	D	(8)(9)	6219271	I	See footnotes

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (MM/DD/YYYY)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned at End of Issuer's Fiscal Year (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

- (Senrigan Capital Management Limited, a Cayman Islands limited company ("SCM") with a business address of PO Box 309, Uglund House, Grand Cayman, KY-1104, is filing this Form 4 jointly with Senrigan Capital Group Limited, a Hong Kong limited company ("SCG"), and Nick Taylor, a citizen of the United Kingdom each of whom has a business address of 11th Floor, LHT Tower, 31 Queens Road Central, Hong Kong and may be deemed to have a pecuniary interest in securities reported by it on this Form 5 ("the Subject Securities"). Collectively, these are the "Reporting Persons."
- (SCM advises the accounts of the Senrigan Master Fund Limited, a Cayman Islands limited company, Senrigan US Feeder Fund Limited, a Cayman Islands limited company, and Senrigan Fund Limited, a Cayman Islands limited company (together with Senrigan Master Fund Limited and Senrigan US Feeder Fund Limited, the "Senrigan Funds").
- (SCM, as the investment manager to the Senrigan Funds, may be deemed to be the beneficial owner of the Subject Securities for purposes of Rule 16a-1(a) of the Securities Exchange Act of 1934. Pursuant to an investment advisory agreement between SCM and SCG, SCG may be deemed to be the beneficial owner of the Subject Securities for purposes of Rule 16a-1(a). By virtue of Nick Taylor's position as majority owner of SCM, Nick Taylor may be deemed to be the beneficial owner of the Subject Securities for purposes of Rule 16a-1(a).
- (Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein.
- (REVA Medical Inc. (the "Company") lists a CHES Depositary Instrument, or "CDI," to enable its securities to be traded on the Australian Stock Exchange.
- (Ten CDIs are equivalent to one share of Common Stock and have all the rights and privileges of Common Stock. Following the Options exercise described in footnote 6, as at 31 December 2015, the Reporting Persons held 57,652,301 CDIs, which translate into the 5,765,230 shares of Common Stock.

- (On November 14, 2014, the Company issued 125 convertible notes with a face value of \$100,000 each (the "Convertible Notes") and 4,375,000 options (the "Options") to purchase 4,375,000 shares of the Company's common stock, par value \$0.0001 per share (the "Common Stock") to SCM. On October 2, 2015, the Reporting Persons exercised 100% of the Options to purchase the Common Stock at a purchase price of A\$2.5/USD 2.17 per share. Total purchase price of Common stock upon exercise of the Options was USD \$9,505,781.25.
- (The Convertible Notes are convertible at any time into shares of Common Stock. The conversion price for the Convertible Notes will initially be A\$2.50 per share, subject to adjustment as further described in the Prospectus for Offering of Convertible Notes and Options, dated October 24, 2014 (the "Prospectus"). The number of shares of Common Stock to be issued upon conversion of the Convertible Notes is determined by dividing the face value of the Convertible Note converted (translated from US dollars into Australian dollars at the exchange rate fixed on the subscription date for the Convertible Note) by the conversion price in effect on the conversion date.
- (On 7 July 2016, an institutional seller of 5,874,385 CDIs (see footnote 5 for explanation of CDI) executed a block trade with the Reporting Persons outside the market at a price of .98 AUD. At the prior request and agreement with the Company's senior management and members of the board of directors, on 13 July 2016 the Reporting Persons allocated 1,333,980 of the block trade CDIs to Ann Keating, Robert Thomas, Regina Groves, Robert Stockman, Gorden Nye, and Ross Breckenridge, their families and affiliated entities at a price of .98 AUD, resulting in no gain or loss from the transaction.
- (The Reporting Persons carried all costs, fees and commissions associated with the 13 July allocation, resulting in a net loss to the Reporting Persons of 1,307 AUD. As a result of the block trade and allocation, the Reporting Persons purchased a net 4,540,405 CDI shares of the Company and as at December 31, 2016 therefore had total CDI holdings of 62,192,706 in the Company (equivalent to 6,219,271 Common Stock).

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Senrigan Capital Group Ltd 1504 15TH FLOOR WHEELLOCK HOUSE 20 PEDDER STREET, CENTRAL HONG KONG, K3 00000		X		
Senrigan Capital Management Ltd PO BOX 309, UGLAND HOUSE GEORGE TOWN, E9 00000		X		
Taylor Nicholas 11TH FL,LHT TOWER,31 QUEENS ROAD CENTRAL CENTRAL, K3 1		X		

Signatures

Senrigan Capital Management Limited By: /s/ Nick Taylor Name: Nick Taylor Title: Director

2/14/2017

—Signature of Reporting Person

Date

Senrigan Capital Group Limited By: /s/ Chris Nash Name: Chris Nash Title: Chief Operating Officer

2/14/2017

—Signature of Reporting Person

Date

/s/ Nick Taylor

2/14/2017

—Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.